Prostate Volume In Patients Research Articles

The effects of 5-ARIs on prostate volume in patients with or without heart failure and benign prostate hyperplasia: prospective, comparative study

The effects of 5-ARIs on prostate volume in patients with or without heart failure and benign prostate hyperplasia: prospective, comparative study

Study on the correlation between glycolipids and prostate volume in patients with benign prostatic hyperplasia

To study the clinical correlation between fasting plasma glucose, lipid metabolism, prostate-specific antigen and prostate volume in patients with benign prostatic hyperplasia, and to explore the combined effect as diagnostic indicators. A total of 108 patients with benign prostatic hyperplasia treated in Beijing University of Chinese Medicine Third Affiliated Hospital from June 2021 to March 2023 were retrospectively analyzed as the hyperplasia group, and 98 healthy physical examination personnel were selected as the control group during the same period. Compare the differences in levels of fasting plasma glucose (FPG), total cholesterol (TC), triglycerides (TG), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), small and dense low-density lipoprotein cholesterol (sdLDL-C), homocysteine, lipoprotein a (LPa), prostate specific antigen (PSA), and free prostate specific antigen (fPSA) between two groups of patients. Using Pearson analysis method to analyze the correlation between the above indicators and the size of prostate volume in patients with benign prostatic hyperplasia; using multiple linear regression to analyze the influencing factors of prostate volume enlargement; draw receiver operating characteristic (ROC) curves and analyze the application value of individual and combined detection of HDL, FPG, PSA, and fPSA. The results showed that there were significant differences in HDL, FPG, PSA, and fPSA levels between the control group and the proliferative group(P<0.05). The size of prostate volume is negatively correlated with HDL(r=-0.183, P<0.05) and positively correlated with FPG (r=0.202, P<0.05), PSA(r=0.412, P<0.05), and fPSA(r=0.425, P<0.05). The results of multiple linear regression analysis showed that HDL(P=0.000), FPG(P=0.048), PSA(P=0.044), and fPSA (P=0.012) were risk factors for increased volume of benign prostatic hyperplasia; ROC curve analysis shows that the AUC of HDL, FPG, PSA, and fPSA combined detection is 0.823, which is better than individual detection. In conclusion,HDL, FPG, PSA, fPSA has close correlation with hyperplasia of prostate, the joint detection may has better prediction for benign prostatic hyperplasia.

Correlation of Transrectal Ultrasonography Guided Prostate Biopsy Gleason Score Results with Prostate Volume in Patients with Prostate Specific Antigen Level Between 2.5-10 ng/mL

Correlation of Transrectal Ultrasonography Guided Prostate Biopsy Gleason Score Results with Prostate Volume in Patients with Prostate Specific Antigen Level Between 2.5-10 ng/mL

The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia: A prospective cohort study.

Benign prostatic hyperplasia (BPH) is increasing substantial burden on health care systems. Men with high body mass index (BMI) have bigger prostate volumes (PV) with subsequent increase in lower urinary tract symptoms (LUTS) than men with normal BMI. The purpose of this research was to investigate the correlation between Obesity and PV in patients with BPH. The study included 560 patients (50-80 years) with BPH. Weight and height measured to calculate BMI. TRUS was used to measure PV. Patient demographics such as IPSS score and prostate specific antigen (PSA) were also noted. Patients in the study had a mean age of 65.3 ± 9.45 years and the mean BMI was 23.97 ± 4.89 kg/m2. The mean PV of each BMI group were 37.45 ± 0.81, 57.89 ± 1.52 and 77.94 ± 2.17 (ml) for normal, overweight and obese groups, respectively, and the average PV score was 57.76 ± 1.50 ml. The mean PSA score was 3.26 ± 0.94 (ng/dl) with a range of 0.6-10.4. There was significant correlation between BMI and PV (p = 0.001) as well as between BMI with PSA and IPSS (p = 0.02, 0.001, respectively). The results showing strong correlation between BMI and PV also BMI with PSA and IPSS. Therefore reducing weight may lead to a lower prostate volume in the elderly stage, making LUTS less noticeable and improving quality of life.

Correlation between body mass index and prostate volume in patients with benign prostatic hyperplasia

Introduction. Obstruction due to benign prostatic hyperplasia (BPH) is a common condition in men over 40 years of age. This study determined the association between body mass index (BMI) and preoperative prostate volume (PV).The purpose of the study was to determine whether there is an association between obesity and prostate volume in men with BPH.Materials and methods. The medical records of 96 patients who underwent holmium enucleation of the prostate as a treatment for BPH and who met the inclusion criteria were retrospectively reviewed. The mean age of the patients was (70.6±8.5) years. Correlation analysis was performed to assess the relationship between BMI and prostatic volume.Results. A total of 96 patient charts were analyzed. When assessing the relationship between BMI and prostate volume, a statistically significant direct correlation of moderate strength was found (ρ = 0.456, p &lt; 0.001). Patients with prostate volume &gt; 75 mL were significantly more likely to have urinary retention (p &lt; 0.001; OR = 4.7; 95% CI: 1.9−11.4).Discussion Studies on larger patient samples are needed to verify the results against true population figures.Conclusion A positive correlation between BMI and prostate volume has been established.

TO STUDY THE BURDEN OF MALES PRESENTING WITH LOWER URINARY TRACT SYMPTOMS(LUTS), ULTRASONOGRAPHIC CORRELATION OF PROSTATE AND UROFLOWMETRY, INTERNATIONAL PROSTATE SYMPTOM SCORE(IPSS) SCORING IN ALL PATIENTS PRESENTING TO TERTIARY CARE CENTER, HAPUR.

Introduction: Men with lower urinary tract symptoms based on International Prostatic Symptoms Scale, suggestive of BPH. Trans-abdominal sonogram,gives the prostate volume.Further evaluation with uroowmetry for PVR urine gives an idea about severity of LUTS.So the purpose of this study was to assess the size of the prostate gland in patients with lower urinary tract symptoms and to compare it with uroometry along with IPSS scoring. This study may be useful to the surgeons in terms of prevalence of prostate enlargement in each decade after 40 years. To study Aim: the correlation of ultrasonographic prostate size with uroowmetry and International Prostate Symptom Score (IPSS) in all male patients presenting with Lower Urinary Tract Symptoms(LUTS). 80 patients presented with Materials And Methods: LUTS (Lower urinary tract symptoms), after clinical history and examination, patients underwent ultrasonography for prostate size. Uroowmetric parameters were recorded. IPSS score of all patient were recorded. IPSS scoring in maximum patients w Results: ere &gt;20 in 90% of patients. In transabdominal USG, out of 80 patients,77 patients prostate volume was more than 35 gms. The patients had a T avg of &lt;10sec, 72% of the patients had value between 10-15sec. 28% of the patients had value &gt;15sec

Relationship between serum indirect bilirubin and prostate volume in patients with benign prostatic hyperplasia: a cross-sectional study

Due to its anti-oxidative effects, bilirubin may protect against a spectrum of diseases. However, the role of bilirubin in patients with benign prostatic hyperplasia (BPH) is poorly explored. This study aimed to investigate the cross-sectional associations between serum indirect bilirubin (IBIL) and prostate volume (PV) in patients with BPH. The medical records of 722 BPH patients were retrospectively analyzed. Body mass index (BMI) was calculated as body weight (kg)/height (m)2. PV was obtained as height (cm) × width (cm) × length (cm) × π/6. Other biochemical indexes were measured by the automatic biochemical analyzer. A univariable linear regression analysis was performed to detect confounders. The IBIL-PV relationship was examined using unadjusted and covariate-adjusted regression models. Furthermore, a segmented linear regression was conducted to analyze the linear trend of IBIL levels and PV. Finally, the sensitivity analysis was stratified by BMI and low-density lipoprotein cholesterol (LDL-C) cutoffs. In this study, the mean age of the patients was 68 (range, 43-93) years. By univariable line regression test, we observed that PV was positively correlated with age, BMI, and LDL-C (β=0.113, 0.096, and 0.135, respectively). IBIL was negatively associated with PV in full adjusted model in men age ≤75 years (β=-1.01; 95% CI: -1.81, -0.22; P=0.01). A statistically significant inverse trend was observed between serum IBIL intervals and PV in patients aged ≤75 years (adjusted for age, BMI, and LDL-C, P for trend =0.015). In sensitivity analysis, significantly negative IBIL-PV relationship only existed in men with normal BMI (adjusted β=-1.328; 95% CI: -2.467, -0.190; P=0.022), overweight men (adjusted β=-1.296; 95% CI: -2.519, -0.074; P=0.038), and men with normal LDL-C level (adjusted β=-1.017; 95% CI: -1.869, -0.164; P=0.019). IBIL is negatively associated with PV in the non-obese population ≤75 years with normal LDL-C. These results suggest that higher serum IBIL possibly provides a degree of protection to BPH by mitigating oxidative stress (OS) related to aging and lipid peroxidation. Nevertheless, these preliminary findings from a single-center, retrospective study have limitations and need to be confirmed by future studies.

Intravesical prostatic protrusion and prostate volume in patients with acute urine retention

Background: To study the prevalence of significant Intravesical Prostatic Protrusion (IPP) in patients presenting with acute urinary retention (AUR) due to Benign prostatic hyperplasia (BPH) and to study the correlation between intravesical prostatic protrusion and prostatic volume.Methods: We assessed 68 men between the ages 45 to 85 who presented with acute urinary retention. Initial assessment included detailed clinical history, International Prostate Symptom Score (IPSS) and Quality of Life assessments and a transabdominal ultrasonogram to measure Prostate Volume (PV) and Intravesical Prostatic Protrusion (IPP). The degree of IPP was determined by the distance from the tip of the protrusion to the circumference of the bladder at the base of the prostate gland. Patients with IPP &gt;10 mm were taken have significant IPP and those ≤10 mm was taken to be insignificant. Statistical analysis included descriptive analysis and Pearson’s correlation coefficient.Results: Of the 68 patients in our study with resented with AUR, 29 patients (42.9%) had significant IPP. Mean IPP was 9.81mm with a standard deviation of 5.41 mm. All patients with significant IPP had a severe IPPS grade. IPP had a statistically significant correlation with prostatic volume.Conclusions: The IPP as assessed by transabdominal ultrasound can be used to direct appropriate patients to more aggressive treatment strategies like surgery.

Осознанный подход к выбору консервативной терапии ДГПЖ

The follow-up results, as well as own case study, are presented to evaluate the efficacy and tolerability of creeping palm fruit extract (Permixon) in combination with an α-blocker in patients with lower urinary tract symptoms (LUTS) of moderate severity associated with benign prostatic hyperplasia (BPH). The follow-up study involved 58 male patients aged 48 to 70 years (mean age 60.1±3.4 years). Group 1 (n=30) was assigned a combined therapy with Tamsulosin (alpha blocker) (0.4 mg once daily) and Permixon (1 capsule, 160 mg, twice daily) for 6 months. Group 2 (n=28) underwent monotherapy with Tamsulosin (0.4 mg once daily) also for 6 months. The observed patients underwent a comprehensive urological examination, which included an assessment of symptoms in points on IPSS (International Prostate Symptom Score); laboratory and instrumental studies. The patients were examined before and 3 and 6 months after therapy initiation. Therapy tolerability was assessed by the frequency and severity of local and/or systemic adverse events. Initially, the maximum urinary flow rate, residual urine volume, IPSS and prostate volume in patients from both groups did not differ statistically significantly. In the intergroup comparison, by 6 months of treatment (versus the treatment initiation), the average urinary flow rates in group 1 increased almost twice, and in group 2 only by 18% (p&lt;0.05). There was a decrease in the residual urine volume in patients of groups 1 and 2, respectively, by 52.6 and 22.6% (p&lt;0.05). The sum of the IPSS decreased by 46.1 and 21.5%, respectively (p&lt;0.05). At the same time, no significant tendency in the volume of the prostate gland in group 2 were revealed in the first 3 months of therapy, However, after 6 months there was an increase in the average prostate volume by 8.8%. In group 1, prostate volume decreased by almost 20% over 6 months of therapy. The tolerability of the studied drug was satisfactory; no adverse events were noted in any patient. Permixone is an effective drug with a high safety profile within the pathogenetic therapy of BPH, affecting a number of factors concerning the development and progression of this disease KEYWORDS: benign prostatic hyperplasia, lower urinary tract symptoms, microcirculation, Serenoa repens, phytotherapy, Laser Doppler flowmetry FOR CITATION: Nashivochnikova N.A. Informed method of choice concerning conservative therapy of BPH. Russian Medical Inquiry. 2022;6(4):187–194 (in Russ.). DOI: 10.32364/2587-6821-2022-6-4-187-194.

Outcomes of Prostate Artery Embolisation in Patients with Severe Symptoms of Benign Prostate Hyperplasia.

BackgroundBenign prostatic hyperplasia (BPH) is associated with severe lower urinary tract symptoms (LUTS). The severity of LUTS is assessed by the International Prostate Symptoms Score (IPSS). Prostate artery embolisation (PAE) is a newly available method for combating LUTS. This study aims to assess the outcomes of PAE in reducing LUTS and prostate volume in patients with BPH.MethodsPatients diagnosed with BPH with severe LUTS who had undergone PAE were included. Their IPSS score was ≥ 20 despite medical therapy. PAE was performed via the unilateral femoral artery using various types of embolic material. Bilateral or unilateral embolisation of the prostate artery was considered a technical success. The severity of LUTS pre- and post-PAE were assessed using IPSS while prostate volume pre- and post-PAE were assessed by ultrasound and magnetic resonance imaging (MRI).ResultsNinety percent of patients had technical success and one required transurethral resection of the prostate (TURP). The mean IPSS reduction at the final follow-up was 12.9 (P < 0.028). The mean reduction of prostate volume at the last follow-up by ultrasound was 114.99 mL (P < 0.028) and by MRI was 29.17 mL (P < 0.028).ConclusionPAE is safe and effective in reducing severe LUTS and prostate gland volume in BPH patients.

Study on Estimation of Serum Prostate Specific Antigen Level and Prostate Volume with Trans-Abdominal Ultrasonography Finding in Benign Prostate Hypertrophy at Tertiary Care Hospital : A Cross Sectional Descriptive Study

Introduction: The periurethral and transition zones of the prostatic gland develop benign prostatic hyperplasia and represent an inevitable phenomenon for the ageing male population. Prostatic specific antigen, is a serine protease, level rises in the blood if the barrier between thelining epithelium and the blood stream is damaged. Benign prostatic hyperplasia, prostatic carcinoma and prostatitis are three common diseases where PSA in the serum is raised. Prostate volume also increases according to age, which can be estimated by trans-abdominal ultrasonography.&#x0D; Objective: The aim of the study is to estimate the PSA level in blood and its relationship with prostate volume in benign prostatic hyperplasia patients.&#x0D; Methodology: It is a descriptive cross-sectional study which was carried out between a periods of 1st April 2018 to 31st March 2019 at Birat Medical College Teaching Hospital. All the patients diagnosed with benign prostate hyperplasia at the department of urology were included in the study. Blood samples of patients were analyzed for Prostate specific antigen level estimation by chemiluminescence immunosorbent assay. Prostatic volume of the patients was measured by Transabdominal ultrasound technique. Data were entered and analyzed in Microsoft Excel.&#x0D; Results: A total of 68 patients were diagnosed with benign prostate hyperplasia. The mean age of the patients was 61.8±12.3 years. The maximum number 23 of patients with BPH was there in age group 51-60. The maximum no of patients 38 were having their PSA level between the range of 4.0-10.0 ng/ml. The maximum no of patients 28 was having Prostate volume in the range of 40-60 gm. The maximum number of patients 31 was having diabetes mellitus as a co-morbid association. The maximum mean PSA level and prostate volume in the patients were observed in age group &gt;80 years,which was 20.1±8.6 ng/ml and &gt;80 gm respectively.&#x0D; Conclusion: The prostate specific antigen level and prostate volume both increase in advance age group of patients suffering with benign prostate hyperplasia.

The Association between Obesity and Prostate Volume in Patients with Benign Prostatic Hyperplasia

Background and Aim:Prostate histological enlargement known as Benign Prostatic Hyperplasia (BPH) is the major challenge for aging men with substantial burden on the health care system. It is associated with incomplete emptying sensations and impedance in flow due to symptoms of the lower urinary tract. Patient of higher body mass index (BMI) or obese have larger prostate volume (PV) and increase in lower urinary tract symptoms (LUTS) compared to normal BMI patient as reported by many researchers. The current study aim was to correlate the association between obesity and prostate volume in BPH patients. Materials and Methods: This cross-sectional was conducted on 140 BPH patients with 45 years to 75 years age range admitted in the department of Urology, DHQ Teaching Hospital, Dera Ismail Khan for six months duration from July 2020 to December 2020. BMI of each individual was calculated using height and weight measurements. Measuring tape was used to measure waist circumference (WC) while Prostate volume (PV) was measured with Transrectal Ultrasound (TRUS). Demographic and clinical parameters such as diabetes, smoking, prostate specific antigen (PSA) and hypertension were recorded on pre-designed proforma. Outcome variables were BMI and prostate volume. Results:Patients were divided into three categories based on BMI namely Obese, overweight and normal. Mean value for age and BMI was 61.34±5.324 and 26.89±4.13 respectively. Mean PV of Obese, overweight and normal BMI were 61.34±7.5, 59±3.10 and 50.91±8.5 cm3 respectively. The PV average score was 58.42±6.53 cm3. The mean value for waist circumference (WC) and PSA were 97.20 and 5.10±3.23 with 1.2-5.9 range respectively. The correlation between PV and BMI as well as between WC and PV, diabetes, smoking and hypertension shown no significance (p value=0.195). However, PSA and PV correlation give significant (p value 0.001-0.009) correlation. Conclusion:Central obesity plays a key role in developing and promoting BPH. The highest prevalence of BPH was found in patients with BMI &gt;30kg/m2 while lowest in men of BMI &lt;23 kg/m2. The current study found higher frequency of BPH among patients with WC &gt;90 cm and lowest in men of WC &lt;90 cm. A positive correlation was found between WC, BMI and PV. Individual quality of life affected by LUTS caused by severe risk of BPH due to increase in obesity. Balance diet and physical exercise help in maintaining the healthier BMI among obese and aged men. Keywords: Benign prostate hypertrophy, Bladder outlet obstruction, Prostate volume

ANOVA-Based Magnetic Resonance Imaging in the Diagnosis of Prostate Cancer with Bone Metastasis and Rehabilitation Treatment

This study was to analyze the magnetic resonance imaging (MRI) characteristics of prostate cancer patients with bone metastasis and the difference in the rehabilitation effect of patients with different bone metastases. The MRI, diffusion weighted imaging (DWI), magnetic resonance elastic imaging (MRE), and MRI + DWI + MRE imaging were performed on 200 prostate cancer patients in the First Affiliated Hospital of Kunming Medical University hospital. The prostate-specific membrane antigen (PSMA), prostate-specific antigen (PSA), and prostate volume in patients with bone metastases were analyzed. The sensitivity, specificity, and accuracy of the four detection methods of bone metastases in prostate cancer were detected. In addition, the changes of the bone metabolism index β-special collagen sequence (β-CTX), type I procollagen amino terminal propeptide (PINP), and osteocalcin (BGP) of the patients were analyzed and compared before and after the treatment. The results showed that the levels of PSMA4 (17.35 ± 51.64 ng/mL) and PSA (15.86 ± 6.33 ng/mL) in nonbone metastatic prostate cancer patients were much lower than those of osteogenic bone metastases (668.95 ± 47.13 ng/mL and 202.15 ± 31.53 ng/mL), mixed bone metastases (637.63 ± 41.35 ng/mL and 186.45 ± 24.86 ng/mL) prostate patients. The sensitivity (96.25%), specificity (89.85%), and accuracy (98.53%) of MRI + DWI + MRE in the prostate cancer bone metastasis were obviously higher than those of MRI (86.46%, 78.31%, and 90.31%), DWI (88.11%, 82.53%, and 91.43%), and MRE (83.36%, 76.94%, and 89.76%). The levels of β-CTX (0.41 ± 0.07 ng/mL), PINP (39.04 ± 6.38 ng/mL), and BGP (17.56 ± 4.22 ng/mL) after treatment in patients with nonbone metastasis prostate cancer were greatly lower than those of osteogenic bone metastases (0.66 ± 0.08 ng/mL, 51.45 ± 7.45 ng/mL, and 33.65 ± 6.14 ng/mL) and patients with mixed bone metastases (0.75 ± 0.12 ng/mL, 53.66 ± 9.22 ng/mL, and 31.24 ± 5.73 ng/mL), showing statistically obvious differences ( P &lt; 0.05 ). In short, the sensitivity, specificity, and accuracy of MRI + DWI + MRE in detection of prostate cancer bone metastasis were better than those of a single examination method, showing significant impacts on the rehabilitation of patients with prostate cancer bone metastasis.

The correlation between obesity and prostate volume in patients with benign prostatic hyperplasia at Charlotte Maxeke Johannesburg Academic Hospital

BackgroundBenign prostatic hyperplasia (BPH) is on the increase placing a substantial burden on health care systems. Recent studies have shown that men with high body mass index (BMI) and central obesity, as denoted by waist circumference (WC) have bigger prostate volumes (PV) with subsequent increase in lower urinary tract symptoms (LUTS) than men with normal BMI. The purpose of this research was to investigate the correlation between Obesity and PV in patients with BPH.MethodsThe study included 178 men aged between 50 and 75 years with BPH seen at Charlotte Maxeke Johannesburg academic hospital (CMJAH) Urology Outpatient Department between September 2018 and February 2019. Weight and height measurements were obtained to calculate BMI. Furthermore, WC was measured using a measuring tape, while a transrectal ultrasound (TRUS) was used to measure PV. Patient demographics, clinical characteristics such as hypertension, diabetes, smoking and prostate specific antigen (PSA) were also noted.ResultsPatients in the study had a mean age of 64.87 ± 6.526 years and the mean BMI was 27.31 ± 3.933 kg/m2. The mean PV of each BMI group were 52.92 ± 38.49, 61.00 ± 33.10 and 64.86 ± 37.46 cm3 for normal, overweight and obese groups, respectively, and the average PV score was 59.36 ± 36.507 cm3. The mean PSA score was 4.30 ± 3.126 with a range of 1.3–6.4, while the mean WC was 98.67 cm. There was no correlation between BMI and PV (p value = 0.195) as well as between PV and WC, hypertension, diabetes or smoking. The results revealed that the relationship between PV with PSA level as well as age was significant (p value = 0.001, p value = 0.009, respectively).ConclusionThe results showed no correlation between BMI and PV. Diabetes and hypertension as well had no positive correlation with PV. A follow-up study may be indicated to look at the correlation between obesity, LUTS and urinary flow rates to establish whether aggressive management of obesity would have significant impact on the management of BPH.

The effect of tamsulosin and dutasteride combination drug therapy on prostate volume in patients with benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is a benign enlargement of the prostatic gland. This study was conducted to measure the improvement of prostate volume after treatment with Tamsulosin and Dutasteride as a combination drug in BPH patient at RSUD Kota Mataram from February 2020 to April 2020. The data were obtained by documenting the medical records of 20 new BPH patients ultrasound before and after 2 months therapy. This study was conducted using a comparative numerical analytical research model. The analysis was carried out by paired T-test in SPSS. A total of 20 medical records observed, the mean age of the study sample was 67.4 years, with the lowest age at 56 years and the oldest were 79 years, and 85% (17) of samples are more than 60 years old. The average prostate volume pre-therapy was 51.71 cc with the lowest volume was 25 cc and the highest volume 118 cc. Average prostate volume post-therapy was 42.38 cc, with the lowest volume was 22 cc and the highest 92 cc. The ratio of prostate volume more than 40 cc at pre-therapy was 50% (10 samples), and after therapy was decreased to 40% (8 samples). There are significant difference in comparison of pre and post-therapy prostate volume.

Implementation of Fuzzy-based Model for Prediction of Prostate Cancer

Cancer is one of the leading causes of death worldwide. One type of cancer that causes death in the male population is prostate cancer. This disease occurs only in men because in women they do not have a prostate appearance. The aim of this study was to compare the accuracy of the model with the predictions of prostate cancer specialists. Prediction is made based on prostate specific antigen data, age, and patient prostate volume. The independent variables in this study were prostate specific antigen, age, and prostate volume. The dependent variable is the risk of prostate cancer using a fuzzy model. The novelty of this study is that the model has a low, moderate, high, and very high prostate cancer risk level output. In the previous article only PCR values were produced. The results show that the proposed fuzzy model provides a PCR value that is within the PCR interval predicted by a specialist doctor can be used properly to help diagnose and analyze the possibility of prostate cancer and is one of the considerations for doctors to decide whether or not a biopsy is needed for these patients.

Relationship of Prostate-Specific Antigen (PSA) and Prostate Volume in Patients with Biopsy Proven Benign Prostatic Hyperplasia (BPH)

Abstract Benign prostatic hyperplasia (BPH) is one of the most common benign tumors in men with prevalence ranging from 50% for men in their 60s to 90% for men in their 80s. The researcher sought to determine the relationship of prostate-specific antigen (PSA) and prostate volume in patients with benign prostatic hyperplasia. This study was based on 33 cases of benign prostatic hyperplasia in the Department of Urology, RSUD Dr. Soetomo Surabaya that diagnosed by histopathology examination. Cases with malignancy, acute urinary retention and prostatitis were excluded. The variables of prostate-specific antigen and prostate volume were examined. The results of this study found that 33 men were enrolled with mean PSA 16,04 ng/ml and a mean prostate volume of 49,13 ml. Overall, 84,8% had PSA level &gt;4 ng/ml and 90,9% had prostate volume &gt;25 ml. Prostate-specific antigen has significant correlation with prostate volume (p=0,019; r=0,362). This study concluded that prostate-specific antigen and prostate volume showed a significant correlation. Keywords : benign prostatic hyperplasia, prostate specific antigen, prostate volumeCorrespondence : anny_sr@fk.unair.ac.id

Free prostate-specific antigen outperforms total prostate-specific antigen as a predictor of prostate volume in patients without prostate cancer.

In the management of benign prostatic hyperplasia (BPH), urology guide- lines recommend medical or surgical treatments according to different prostate volumes (PV). The aim of this study was to analyze the relationships between PV and age, total and free prostate specific antigen (tPSA, fPSA) and fPSA/tPSA ratio in patients without histologically proven prostate cancer. A retrospective analysis was made of the data of 1334 patients who underwent transrectal ultra- sound (TRUS)-guided prostate biopsy between January 2016 and October 2018. A total of 438 patients with available data for age, tPSA and fPSA levels and PV calculated by TRUS were enrolled in the study. Patients with chronic prostatitis pathology in addition to BPH were also noted and evaluated as a separate group. There were significant correlations between PV and age, tPSA, fPSA, fPSA/tPSA ratio (r = 0.210, r = 0.338, r = 0.548, r = 0.363 respectively). In multivariate linear regression analysis, fPSA was found to be the only predictor for PV (p < 0.001) when compared to age (p = 0.097), tPSA (p = 0.979) and fPSA/tPSA ratio (p = 0.425). In patients with chronic prostatitis pathology there were significant correla- tions between PV and age, tPSA, fPSA, fPSA/tPSA ratio (r = 0.279, r = 0.379, r = 0.592, r = 0.359, respectively). The multivariate linear regression analysis showed a signifi- cant correlation only between PV and tPSA and fPSA/tPSA ratio but not with fPSA and age (p = 0.008, p = 0.015, p = 0.430, p = 0.484, respectively). In men with only BPH pathology there were significant correlations between PV and age, tPSA, fPSA, fPSA/tPSA ratio (r = 0.223, r = 0.385, r = 0.520, r = 0.287, respectively) In multivariate linear regression model the significant correlation was shown only between PV and fPSA (p < 0.001). Although tPSA was significantly correlated with PV in patients without prostate cancer, the correlation between fPSA and PV was much stronger. However, it should be kept in mind that the efficacy of fPSA may be limited in patients with clinically unknown prostatic inflammation.

Correlation between intravesical prostatic protrusion and prostate volume in patients presenting with acute urinary retention - A descriptive study

Correlation between intravesical prostatic protrusion and prostate volume in patients presenting with acute urinary retention - A descriptive study

Effect of preoperative prostate volume on the improvement of lower urinary tract symptoms in patients with benign prostatic hyperplasia undergoing transurethral resection of prostate

Introduction: Benign prostate hyperplasia, pathophysiology contributes to bladder outlet obstruction due to functional obstruction caused by gland size enlargement resulting in the lower urinary tract symptoms (LUTS). Objectives: To determine the correlation of the prostate volume with surgical outcomes and postoperative LUTS in patients with benign prostatic hyperplasia (BPH) undergoing transurethral resection of the prostate (TURP). Patients and Methods: Patients with BPH who were refractory for medical treatment enrolled in the study. Patients divided into three groups with attention to their prostate volume conducted by transabdominal ultrasonography. To evaluate patients’ LUTS, the International Prostate Symptom Score (IPSS) questionnaire was filled for all patients preoperatively and during the first and third months follow up sessions. Results: In the current study, mean age of the patients was 66.92 ± 1.08 years. Of 111 patients, eight patients (7.2%) had prostate volume less than 30 cc, 59 patients (53.2%) had prostate volume between 30-60 cc, and 44 patients (39.6%) had prostate volume more than 60 cc. During first month postoperative, mean decrease in IPSS scores in patients with prostate volume less than 30 cc, prostate volume between 30–60 cc and prostate volume more than 30 cc were 27.72 ± 3.53, 27.32 ± 3.37 and 27.45 ± 2.87, respectively. The ANOVA test showed no significant difference between the groups (P= 0.93). Mean decrease in IPSS score during third month postoperative, had no significant difference between the three groups, too (P=0.71). Symptoms alleviation observed in 94.6% and 95.5% of the patients, during first and third months follow-up, respectively. Conclusion: There was no correlation between the IPSS scores decrease and patients’ symptoms recovery and preoperative prostate volume in patients with BPH who underwent TRUP.